NanoTemper Technologies, maker of life science tools for protein characterization, launches its newest system, Dianthus, at the Society for Laboratory Automation and Screening (SLAS2019) conference in Washington, DC. Built to address the demands of drug discovery screening, Dianthus removes the complexity of binding interaction measurements and enables scientists to develop new drugs for every target faster and at lower costs.
"There are two major challenges in drug discovery screening — the need to screen not only more molecules but more diverse ones covering a greater chemical space, and the need to address smaller projects with explorative targets," says Stefan Duhr, CEO of NanoTemper. "Dianthus has the flexibility to address both of these challenges."
Dianthus quickly identifies and ranks hits by quantifying molecular interactions in solution. It does this for any target type in any buffer or bioliquid and measures a wide range of interactions from millimolar down to picomolar Kds, all by consuming the smallest amount of your target and library compounds.
"Speed is a huge advantage and Dianthus is really fast, screening 10,000 compounds per day, which is unmatched in biophysical drug discovery," says Amit Gupta, Product Manager at NanoTemper. "That's only possible because it's very hands-off, with no fluidics so there's no cleaning or rinsing and virtually no downtime. It also uses industry-standard SBS microplates so it easily integrates into a variety of automation workflows."
Dianthus was inspired by our customer's feedback and was built because they demand fast, non-stop, highly sensitive hit screening. See why Dianthus is so important to drug discovery screening or visit nanotempertech.com/dianthus to find out more details. For the most up-to-date information, follow NanoTemper and #speedscreening on LinkedIn, Facebook and Twitter.